LDR Prostate Medical Event Definition. John Wochos, MS Gundersen Lutheran La Crosse, Wisconsin April 22, 2011

Similar documents
A feasibility study of using conventional jaws to deliver IMRT plans in the treatment of prostate cancer *

Aperture Based Inverse Planning AAPM Summer School 2003

Computers and Medicine

While digital techniques have the potential to reduce patient doses, they also have the potential to significantly increase them.

Patient-Assisted Compression Impact on Image Quality and Workflow

The Safety Case and the Risk-Informed Performance-Based Approach for Management of US Commercial Low-Level Waste (Paper #190)

This is a repository copy of Real-time in vivo dosimetry in high dose rate prostate brachytherapy.

Initial Certification

SHTG primary submission process

Consultation for the Formulation of the NMS IR Programme Dr Dave Rayner Formulator Business Leader, Radiation Dosimetry

The Finding Respect and Ending Stigma around HIV (FRESH) Study Intervention Post-Workshop Survey Community Participants

The Finding Respect and Ending Stigma around HIV (FRESH) Study Intervention Workshop Survey Community Participants

Quality control of Gamma Camera. By Dr/ Ibrahim Elsayed Saad 242 NMT

Quality and GLP for Histology and Pathology of Drug Safety Studies

A Brief Introduction to the Regulatory Environment of Medical Device Supervision. CFDA Department of Legal Affairs Liu Pei

Electronic Brachytherapy Sources. Thomas W. Rusch

TOPICS: CT Protocol Optimization over the Range of Patient Age & Size and for Different CT Scanner Types: Recommendations & Misconceptions

Aim. Images for this section: Page 2 of 13

Progress Report from the HDR Brachytherapy Working Party. Margaret Bidmead

8.2.1 Therac-25 Radiation Overdoses

Andalusian Agency for Health Technology Assessment (AETSA)

The Friends and Family Test score is calculated as outlined in the NHS England guidance issued in Oct-14. The calculation is as follows:

Medical Images Analysis and Processing

Quality assurance in the supply chain for pharmaceuticals from the WHO perspective

Primary IVF Conditions for Registration For Assisted Reproductive Treatment Providers under the Assisted Reproductive Treatment Act 2008

LOREM IPSUM XXX MEDICAL DEVICES NEWS OCTOBER 2012 SPECIAL POINTS OF INTEREST: XXX EDITORIAL

2012 ACCE Industry Advisory Board Best Practices Positioning Your Firm After the Great Recession

TGA Discussion Paper 3D Printing Technology in the Medical Device Field Australian Regulatory Considerations

WANT TO PARTICIPATE IN RESEARCH? THERE S AN APP FOR THAT!

How to be a Proactive Patient

3D Brachytherapy with Afterloading Machines

Emerging Technology: Real-Time Monitoring of Treatment Delivery EPID Exit Dose QA

CEOCFO Magazine. Pat Patterson, CPT President and Founder. Agilis Consulting Group, LLC

Initial Experience with a Commercial System for Volumetric Analysis of Patient Specific QA. Katja Langen Mariana Guerrero Shifeng Chen Shh..

A new approach to measure dwell position inaccuracy in HDR ring applicators quantification and corrective QA

A Fast Monolithic System for Proton Imaging. Fritz DeJongh ProtonVDA Inc October 2017

3D Diode Array Commissioning: Building Confidence in 3D QA Technology

Software as a Medical Device (SaMD)

Ludlum Medical Physics

E5 Implementation Working Group Questions & Answers (R1) Current version dated June 2, 2006

Transmission Availability Data System Phase II Final Report

What is a coverage determination?

A Generalized Strategy for 3D Dose Verification of IMRT/VMAT Using EPID-measured Transit Images

IQM Detector Characteristics: Signal reproducibility

SAUDI ARABIAN STANDARDS ORGANIZATION (SASO) TECHNICAL DIRECTIVE PART ONE: STANDARDIZATION AND RELATED ACTIVITIES GENERAL VOCABULARY

June Phase 3 Executive Summary Pre-Project Design Review of Candu Energy Inc. Enhanced CANDU 6 Design

Volumetric Modulated Arc Therapy. David Shepard Swedish Cancer Institute Seattle, WA

Ai Group Submission. in response to the REVIEW OF ELECTRICITY (CONSUMER SAFETY) ACT 2004 ISSUES PAPER

Studies on reduction of exposure dose using digital scattered X-ray removal processing

Studies on reduction of exposure dose using digital scattered X-ray removal processing

Evolution of Research Consortia Increasing Clinical Focus

NEMA XR X-ray Equipment for Interventional Procedures User Quality Control Mode

Mobius3D. Software based IMRT QA

Tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases

LICENSING THE PALLAS-REACTOR USING THE CONCEPTUAL SAFETY DOCUMENT

Joint ICTP/IAEA Advanced School on Dosimetry in Diagnostic Radiology and its Clinical Implementation May 2009

by Artnarong Thansandote, David W. Lecuyer and Gregory B. Gajda Key Words: Microwave radiation leakage, microwave ovens

8/2/2017. Radiologist Responsibilities. Radiologist Responsibilities. Medical Physicist Mammography Equipment Evaluation and Annual Survey

Prescription Drug-Use-Related Software; Establishment of a Public Docket; Request for Comments (Docket No. FDA-2018-N-3017)

YOUR RIGHTS. In Local Authority Services. Texas Department of Aging and Disability Services. Published by

Is the scanned image stored as a color, grayscale, or black and white image? If applicable, what resolution is used?

Canada s Ballast Water Requirements. September 2016

Breast Tomosynthesis. Bob Liu, Ph.D. Department of Radiology Massachusetts General Hospital And Harvard Medical School

3D Bio printing. Nazrawit Mekonnen IT /29/15. "By placing this statement on my webpage, I certify that I have read and understand the GMU

Re: Examination Guideline: Patentability of Inventions involving Computer Programs

Digital Imaging started in the 1972 with Digital subtraction angiography Clinical digital imaging was employed from the 1980 ~ 37 years ago Amount of

JIS G3465 Seamless Steel Tubes for Drilling

IEEE ICES Exposure Limits Above 6 GHz

Phase 2 Executive Summary: Pre-Project Review of AECL s Advanced CANDU Reactor ACR

Ethics in Materials Engineering

HOW TO GET SPECIALTY CARE AND REFERRALS

Reliability Guideline: Generating Unit Operations During Complete Loss of Communications

2005 HSC Notes from the Marking Centre Food Technology

American Nuclear Society

Reliability Guideline: Generating Unit Operations During Complete Loss of Communications

A BALANCING ACT: STREAMLINING METHOD TRANSFERS WITHOUT COMPROMISING COMPLIANCE OR SCIENCE JULIE FROST SENIOR SPECIALIST, QUALITY CONTROL

Half value layer and AEC receptor dose compliance survey in Estonia

7/23/2014. Acknowledgements. Implementing a new digital medical accelerator. New Generation of Medical Accelerators

State of the Art Film Dosimetry

Practical Medical Physics Session: TG-151 Dose Monitoring. August 5, 2013 Katie Hulme, M.S.

Introduction. Chapter 16 Diagnostic Radiology. Primary radiological image. Primary radiological image

Stage 2: eligibility screening. Stage 3: prioritisation. Stage 4: selection

NATIONAL POLICY ON OILED BIRDS AND OILED SPECIES AT RISK

A Guide to Radiochromic Film Dosimetry with EBT2 and EBT3

Who Benefited From Transportation Improvements?

The Cremation (Scotland) Regulations Consultation. Introduction. The regulations

Nancy G. Leveson and Clark S. Turner, An Investigation of the Therac-25 Accidents. Computer 26(7), pp , Jul Presented by Dror Feitelson

PMDA perspective on Quality by Design for pharmaceutical products

Frequently Asked Questions

Consistent with Labeling Final Guidance: Implications for Drug Products

CENTER FOR DEVICES AND RADIOLOGICAL HEALTH. Notice to Industry Letters

TECHNOLOGY QUALIFICATION MANAGEMENT

Drug Safety. Electronic Supplementary Material. Krska J and Morecroft CW

Identifying and Managing Joint Inventions

Registration of Innovative Medical Devices in China

FDA Oversight Of Drug Safety: What Works, What Doesn t. Geoffrey Levitt Chief Counsel, Regulatory and Research Wyeth Pharmaceuticals August 24, 2006

Exposure Indices and Target Values in Radiography: What Are They and How Can You Use Them?

Medical Devices cyber risks and threats

Applying Advanced Technologies to Improve NPP Productivity

Questioning $1 Million Fee in a Needle Deal

Transcription:

LDR Prostate Medical Event Definition John Wochos, MS Gundersen Lutheran La Crosse, Wisconsin April 22, 2011

Conflicts of Interest NONE Three LDR Medical Events at GLMC

Outline Definition of Medical Event Recent Prostate Medical Events Significance / Purpose of Medical Event Radiation Oncology Safety Issues Wisconsin LDR Prostate Medical Events NRC, ASTRO position Proposed NCCAAPM Recommendation

Philosophy I am NOT a Tea Party Member I do believe there is a strong role for regulators in the use of radiation and radioactive material I do think Radiation Oncology needs significant work in reporting and compiling incidents I do think each institution needs to periodically review procedures from a patient endpoint perspective.

Oct 24, 2010

Definition of Medical Event

Definition cont.

Definition Details & Prostate LDR Improper Administrations implies the sources were not administered according to the prescription What is the Prescribed Dosage? Many have taken this to be D90; the dose received by 90% of the target (PTV or prostate)

RTOG Protocol 0232 Study designed to compare External Beam with LDR prostate brachytherapy (no where are regulatory implications mentioned). CTV = Prostate PTV = CTV + (2-5mm) all directions except Posterior CT 3-5 weeks post procedure per protocol D90 = 90%-130% Acceptable D90 = 80%-90% OR D90>130% Unacceptable D90 < 80%

Philadelphia VA 2008 LDR Prosate Medical Events Analysis by Hagan, et.al., (Brachytherapy, in press) of 62 of the reported Medical Events at the VA Post implant Day 1 CT images were used to evaluate the implants. Edema resulted in a 56% increase in volume (SD 56% also) over the intraoperative ultrasound. Correcting for this edema reduces the number of MEs to 20 using dose criteria.

Cont. Philadelphia VA MEs Re-evaluation based on total activity (strength) 11 cases had >20% of the seeds beyond the treatment site (included designed margin). 3 of these had >40% outside treatment site. 10 of these 11 cases also fail the D90 >80% criteria and the one that did not had questionable volume

NRC Reported Prostate LDR Med Events (Jan 2010 March 2011) State Level Comments Colorado 32% underdose mistake Air Kerma and Activity Kentucky D90 5.2Gy vs 133 planned Not acknowledge by Institution 27% mistake Air Kerma and Activity Illinois Missed gland by 4-5 cm Indiana D90 72% D90 64% "Dose Received" 44% "Dose Received" 44% North Carolina Peripheral implant; seeds outside gland 59% discovered day of implant Ohio 67% of Presc Dose 75% of Presc Dose Dose <20% of prescribed Cold Cold Cold 72% 68% 71% D90 63% aborted implant 13 seeds in bladder Bones too narrow

Cont. MEs 2010-2011 State Level Comments Louisianna D90 = 9% Missed by 3 cm Nevada 79% of Prescribed Connecticut D90 58% Gave external beam boost D90 = 59% felt to be adequate coverage Mississippi VA 10 cold events D90 < 80% 1 cold event D90 < 50% Missouri 11% of prescribed

Cont. MEs 2010-2011 State Level Comments Wisconsin D90 differ 20% D90 = 75% D90 = 75% D90 = 77% D90 = 78% D90 = 121% D90 = 121% D90 = 55% D90 = 78% D90 = 74% D90 = 64% D90 = 75% Overdose Overdose Overdose Overdose Overdose Overdose Underdose Underdose Underdose Underdose D90 = 118% D90 = 69% D90 = 77% D90 = 79% D90 = 70%

NRC Reported MEs 2010-2011 for LDR Prostate Brachytherapy Nine state with two or fewer events One state (Indiana) with 4 events One state (Mississippi) with 11 events, all VA One state (Ohio) with 11 events One state (Wisconsin) with 28 events

Possible Conclusions From Report Medical Events Three states do most of the LDR prostate seed implants? Three states perform significantly worse prostate seed implants? Three states (really two), in particular Wisconsin, have radiation regulators that are investigating differently?

Report Non-Dosimetry MEs *W Butler ABS 2011 20 Gross target misses or wrong target treated 9 wrong strength used 11 leaking sources (mostly MICK jams) 8 reports of lost seeds 1 prescription error (monotherapy vs. boost) 1 wrong patient (and I-125 vs Pd-103) 3 shipping errors

Nov 21, 2010

August 10, 2010 NRC Proposed Amendment voted down Unanimous vote by 5 commissioners NRC staff was recommended to work with their Advisory Committee and the Medical Community to develop a new approach.

What happened at Gundersen 3 on-site visits 2 conference calls July 2010 initial on-site inspection indicated we had established criteria, we were thanked and told there would like be no recommendations Follow-up phone call indicated they did not like our criteria. We needed to establish our own criteria and implement them. Subsequent follow up visit September 2010

September 2010 visit Long discussions on criteria. We did suggest they follow the NRC recommendation and back off on the grey zone cases, zeroing in on clear events. Again, we were told we could establish our criteria and then we were required to stand by it (sounds like phone call recommendation)

Gundersen Initial Criteria and Rationale (Pd-103 exclusively) Since D90 of 80% is acceptable by RTOG standards, a level 20% below that should be an event. Alternatively, if D90 of 90% is a good implant, a D90 of 70% could be an event Upper limit for Pd-103 less well defined, from Brachytherapy 8, D90>140% as upper event. Urethra, no clear limit in literature Bladder, no clear limit in literature Rectum: ESTRO 2cc < 100%

Subsequent Conference Call We could pick our own criteria and live by it as long as it was the State s criteria. We were told our interest was clinical results, their interest was a regulation. They felt the +/-20% dose in the regulations was all that was needed. The range of dose recommended in the regulation was intended for I-131 thyroid treatment and dose not apply here. Thus, a D90 of 100% is the implied prescription.

What we agreed on D90 < 80% is event D90 > 160% is event (gave us higher value for Pd-103) Subsequent review over 2+ years indicated 3 events out of 187 implants. D90 = 78% (PSA 11.83 to 0.54) D90 = 71% (Follow-up April 22, 2011) D90 = 77% (PSA 16.16 to 0.06)

Example of Med Event Contouring uncertainty

D90 of 80% within uncertainty

Definition of Medical Event Improper Administration of radioactive material should we be looking at the RESULT of the procedure to determine if the Administration was Improper? Probably, but.. Total Dosage differs by more than 20% from intended. -->should we be looking at dose? Or, administration of the radioactive material?

ASTRO Working Group Problems in Using Dose Dose based definition has many problems Timing of post implant imaging Imaging modality differences Observer variability Planning margins used vary Planning system uncertainties Seed migration (administration of material vs. result)

ASTRO Working Group Conclusion If a dose based definition for permanent implants is applied strictly many medically acceptable implants would be inappropriately classified as a Medical Event and rather than achieving the intended goal of patient safety, there will be a detrimental effect on brachytherapy.

ASTRO Recommendation Source strength based criterion (>20% of source strength implanted outside PTV) is more appropriate for defining ME in permanent brachytherapy.

Thomadsen Proposal Proposed definition For permanent prostate implants, a medical event should be defined when either: A. For the target, D 90 <70% of the clinical target volume (CTV) AND Less than 5% of sources occupy any octant of the PTV, except by design (e.g. for preservation of normal tissue or escalated treatment to a particular region), as specified in the written directive. B. For the normal tissues, 1. For the bladder and rectum, the D 5cc on post-implant dosimetry exceeds 150% of the prescription dose OR 2. For the urethra, the D 5cc on post-implant dosimetry exceeds 150% of its value on the planned, approved dose distribution.

Wochos Request NCCAAPM submit a letter to Wisconsin Radiation Safety Section requesting they hold off on the enforcement of a Medical Event using D90 criteria of <80% or >140%. Wait for NRC guidance. There is no radiation safety benefit being seen by the patients (of the 28 MEs found there are NO adverse reactions). Why enforce an ambiguous regulation when there is no benefit to anyone? This is a waste of resources for both the Medical Institutions and the Radiation Section Staff

Until Further Guidance Received Current regulation is Dose based There is still a need to call a bad implant a Medical Event D90 was not invented as a regulatory tool, but it is being used as a quantitative measure of implant quality Higher D90 s have better outcomes. But D90 s of 80% still have satisfactory outcomes compared to other modalities Suggest a D90 < 60% for the time being

Radiation Oncology & Safety Need to reduce number of incidents (not limited to Medical Events). Even though percent of incidents is low, the results can be horrific (Cure, palliation, side effects, death). Need a national data base on incidents and near misses. Both at institution and national level we need to determine methods to reduce errors. Outside professional review (peer review, e.g. ACR survey (ASTRO)

Acknowledgements Bruce Thomadsen Mary Ellen Jafari Kimberly Schmidt Kari Adank (Compliance)

Feb 6, 2011